Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Becton, Dickinson & Co., solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Becton, Dickinson & Co. debt to equity ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Becton, Dickinson & Co. debt to capital ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Becton, Dickinson & Co. debt to assets ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Becton, Dickinson & Co. financial leverage ratio decreased from Q4 2021 to Q1 2022 but then slightly increased from Q1 2022 to Q2 2022. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Becton, Dickinson & Co. interest coverage ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |
Debt to Equity
Becton, Dickinson & Co., debt to equity calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Current debt obligations | 1,051) | 1,064) | 500) | 2,033) | 1) | 1,737) | 707) | 1,630) | 4,357) | 2,456) | 1,309) | 2,168) | 3,057) | 3,254) | 2,601) | 1,900) | 202) | 703) | 203) | 453) | 1,224) | 1,974) | 1,001) | 1,351) | 1,651) | 1,951) | ||||||||
| Long-term debt, excluding current portion | 17,584) | 16,360) | 17,110) | 15,700) | 17,718) | 16,082) | 17,224) | 17,090) | 16,809) | 16,949) | 18,081) | 18,016) | 17,556) | 17,817) | 18,894) | 20,350) | 22,589) | 22,095) | 18,667) | 18,563) | 9,082) | 9,043) | 10,550) | 10,561) | 10,864) | 10,858) | ||||||||
| Total debt | 18,635) | 17,424) | 17,610) | 17,733) | 17,719) | 17,819) | 17,931) | 18,720) | 21,166) | 19,405) | 19,390) | 20,184) | 20,613) | 21,071) | 21,495) | 22,250) | 22,791) | 22,798) | 18,870) | 19,016) | 10,306) | 11,017) | 11,551) | 11,912) | 12,515) | 12,809) | ||||||||
| Shareholders’ equity | 24,525) | 24,160) | 23,677) | 24,135) | 24,826) | 24,663) | 23,765) | 24,022) | 20,951) | 21,202) | 21,081) | 21,497) | 21,310) | 21,403) | 20,994) | 21,358) | 21,152) | 21,247) | 12,948) | 12,587) | 7,963) | 7,583) | 7,633) | 8,033) | 7,666) | 7,223) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to equity1 | 0.76 | 0.72 | 0.74 | 0.73 | 0.71 | 0.72 | 0.75 | 0.78 | 1.01 | 0.92 | 0.92 | 0.94 | 0.97 | 0.98 | 1.02 | 1.04 | 1.08 | 1.07 | 1.46 | 1.51 | 1.29 | 1.45 | 1.51 | 1.48 | 1.63 | 1.77 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.46 | 0.48 | 0.50 | 0.53 | 0.55 | 0.55 | 0.57 | 0.59 | 0.64 | 0.60 | 0.58 | 0.60 | 0.61 | 0.62 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 0.73 | 0.72 | 0.71 | 0.72 | 0.68 | 0.66 | 0.65 | 0.75 | 0.77 | 0.81 | 0.83 | 0.87 | 0.89 | 0.95 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 0.73 | 0.76 | 0.75 | 0.79 | 0.81 | 0.87 | 0.93 | 0.97 | 1.05 | 1.10 | 1.07 | 1.10 | 1.16 | 1.25 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.66 | 0.65 | 0.64 | 0.64 | 0.66 | 0.69 | 0.60 | 0.61 | 0.62 | 0.68 | 0.63 | 0.65 | 0.63 | 0.64 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 0.85 | 0.87 | 0.80 | 0.77 | 0.50 | 0.54 | 0.51 | 0.51 | 0.56 | 0.66 | 0.49 | 0.55 | 0.50 | 0.58 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.49 | 0.50 | 0.51 | 0.60 | 0.60 | 0.57 | 0.49 | 0.49 | 0.51 | 0.52 | 0.51 | 0.50 | 0.50 | 0.50 | 0.51 | 0.57 | 0.56 | 0.67 | — | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 0.06 | 0.06 | 0.07 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | 0.09 | 0.07 | 0.14 | 0.13 | 0.12 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.71 | 0.65 | 0.64 | 0.67 | 0.70 | 0.70 | 0.66 | 0.67 | 0.72 | 0.91 | 0.71 | 0.82 | 0.80 | 0.74 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).
1 Q2 2022 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 18,635 ÷ 24,525 = 0.76
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Becton, Dickinson & Co. debt to equity ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
Debt to Capital
Becton, Dickinson & Co., debt to capital calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Current debt obligations | 1,051) | 1,064) | 500) | 2,033) | 1) | 1,737) | 707) | 1,630) | 4,357) | 2,456) | 1,309) | 2,168) | 3,057) | 3,254) | 2,601) | 1,900) | 202) | 703) | 203) | 453) | 1,224) | 1,974) | 1,001) | 1,351) | 1,651) | 1,951) | ||||||||
| Long-term debt, excluding current portion | 17,584) | 16,360) | 17,110) | 15,700) | 17,718) | 16,082) | 17,224) | 17,090) | 16,809) | 16,949) | 18,081) | 18,016) | 17,556) | 17,817) | 18,894) | 20,350) | 22,589) | 22,095) | 18,667) | 18,563) | 9,082) | 9,043) | 10,550) | 10,561) | 10,864) | 10,858) | ||||||||
| Total debt | 18,635) | 17,424) | 17,610) | 17,733) | 17,719) | 17,819) | 17,931) | 18,720) | 21,166) | 19,405) | 19,390) | 20,184) | 20,613) | 21,071) | 21,495) | 22,250) | 22,791) | 22,798) | 18,870) | 19,016) | 10,306) | 11,017) | 11,551) | 11,912) | 12,515) | 12,809) | ||||||||
| Shareholders’ equity | 24,525) | 24,160) | 23,677) | 24,135) | 24,826) | 24,663) | 23,765) | 24,022) | 20,951) | 21,202) | 21,081) | 21,497) | 21,310) | 21,403) | 20,994) | 21,358) | 21,152) | 21,247) | 12,948) | 12,587) | 7,963) | 7,583) | 7,633) | 8,033) | 7,666) | 7,223) | ||||||||
| Total capital | 43,160) | 41,584) | 41,287) | 41,868) | 42,545) | 42,482) | 41,696) | 42,742) | 42,117) | 40,607) | 40,471) | 41,681) | 41,923) | 42,474) | 42,489) | 43,608) | 43,943) | 44,045) | 31,818) | 31,603) | 18,269) | 18,600) | 19,184) | 19,945) | 20,181) | 20,032) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to capital1 | 0.43 | 0.42 | 0.43 | 0.42 | 0.42 | 0.42 | 0.43 | 0.44 | 0.50 | 0.48 | 0.48 | 0.48 | 0.49 | 0.50 | 0.51 | 0.51 | 0.52 | 0.52 | 0.59 | 0.60 | 0.56 | 0.59 | 0.60 | 0.60 | 0.62 | 0.64 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.31 | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 | 0.36 | 0.37 | 0.39 | 0.38 | 0.37 | 0.38 | 0.38 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 0.42 | 0.42 | 0.42 | 0.42 | 0.40 | 0.40 | 0.40 | 0.43 | 0.44 | 0.45 | 0.45 | 0.46 | 0.47 | 0.49 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 0.42 | 0.43 | 0.43 | 0.44 | 0.45 | 0.47 | 0.48 | 0.49 | 0.51 | 0.52 | 0.52 | 0.52 | 0.54 | 0.56 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.40 | 0.39 | 0.39 | 0.39 | 0.40 | 0.41 | 0.38 | 0.38 | 0.38 | 0.41 | 0.39 | 0.39 | 0.39 | 0.39 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 0.46 | 0.46 | 0.44 | 0.43 | 0.33 | 0.35 | 0.34 | 0.34 | 0.36 | 0.40 | 0.33 | 0.35 | 0.33 | 0.37 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.33 | 0.34 | 0.34 | 0.37 | 0.37 | 0.36 | 0.33 | 0.33 | 0.34 | 0.34 | 0.34 | 0.33 | 0.34 | 0.33 | 0.34 | 0.36 | 0.36 | 0.40 | — | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 0.05 | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | 0.07 | 0.06 | 0.06 | 0.08 | 0.07 | 0.12 | 0.11 | 0.10 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.41 | 0.39 | 0.39 | 0.40 | 0.41 | 0.41 | 0.40 | 0.40 | 0.42 | 0.48 | 0.41 | 0.45 | 0.44 | 0.43 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).
1 Q2 2022 Calculation
Debt to capital = Total debt ÷ Total capital
= 18,635 ÷ 43,160 = 0.43
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Becton, Dickinson & Co. debt to capital ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
Debt to Assets
Becton, Dickinson & Co., debt to assets calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Current debt obligations | 1,051) | 1,064) | 500) | 2,033) | 1) | 1,737) | 707) | 1,630) | 4,357) | 2,456) | 1,309) | 2,168) | 3,057) | 3,254) | 2,601) | 1,900) | 202) | 703) | 203) | 453) | 1,224) | 1,974) | 1,001) | 1,351) | 1,651) | 1,951) | ||||||||
| Long-term debt, excluding current portion | 17,584) | 16,360) | 17,110) | 15,700) | 17,718) | 16,082) | 17,224) | 17,090) | 16,809) | 16,949) | 18,081) | 18,016) | 17,556) | 17,817) | 18,894) | 20,350) | 22,589) | 22,095) | 18,667) | 18,563) | 9,082) | 9,043) | 10,550) | 10,561) | 10,864) | 10,858) | ||||||||
| Total debt | 18,635) | 17,424) | 17,610) | 17,733) | 17,719) | 17,819) | 17,931) | 18,720) | 21,166) | 19,405) | 19,390) | 20,184) | 20,613) | 21,071) | 21,495) | 22,250) | 22,791) | 22,798) | 18,870) | 19,016) | 10,306) | 11,017) | 11,551) | 11,912) | 12,515) | 12,809) | ||||||||
| Total assets | 54,786) | 53,363) | 53,866) | 54,333) | 54,921) | 54,748) | 54,012) | 53,959) | 53,516) | 51,952) | 51,765) | 52,233) | 52,598) | 52,932) | 53,904) | 53,977) | 54,573) | 55,363) | 37,734) | 37,166) | 24,121) | 24,318) | 25,586) | 26,016) | 26,236) | 26,046) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Debt to assets1 | 0.34 | 0.33 | 0.33 | 0.33 | 0.32 | 0.33 | 0.33 | 0.35 | 0.40 | 0.37 | 0.37 | 0.39 | 0.39 | 0.40 | 0.40 | 0.41 | 0.42 | 0.41 | 0.50 | 0.51 | 0.43 | 0.45 | 0.45 | 0.46 | 0.48 | 0.49 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 0.23 | 0.23 | 0.24 | 0.25 | 0.25 | 0.25 | 0.26 | 0.27 | 0.29 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 0.22 | 0.22 | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 | 0.22 | 0.23 | 0.24 | 0.24 | 0.25 | 0.25 | 0.26 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 0.24 | 0.24 | 0.24 | 0.25 | 0.26 | 0.27 | 0.28 | 0.29 | 0.30 | 0.31 | 0.31 | 0.31 | 0.33 | 0.34 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.23 | 0.23 | 0.24 | 0.23 | 0.24 | 0.24 | 0.23 | 0.24 | 0.24 | 0.26 | 0.26 | 0.26 | 0.25 | 0.26 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 0.28 | 0.29 | 0.29 | 0.28 | 0.19 | 0.20 | 0.20 | 0.21 | 0.21 | 0.23 | 0.20 | 0.22 | 0.21 | 0.22 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 0.28 | 0.28 | 0.28 | 0.31 | 0.31 | 0.31 | 0.27 | 0.28 | 0.28 | 0.29 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.30 | 0.31 | 0.34 | — | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 0.04 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.07 | 0.06 | 0.11 | 0.10 | 0.10 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 0.22 | 0.21 | 0.22 | 0.22 | 0.23 | 0.23 | 0.22 | 0.23 | 0.24 | 0.27 | 0.23 | 0.26 | 0.25 | 0.24 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).
1 Q2 2022 Calculation
Debt to assets = Total debt ÷ Total assets
= 18,635 ÷ 54,786 = 0.34
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Becton, Dickinson & Co. debt to assets ratio improved from Q4 2021 to Q1 2022 but then deteriorated significantly from Q1 2022 to Q2 2022. |
Financial Leverage
Becton, Dickinson & Co., financial leverage calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Total assets | 54,786) | 53,363) | 53,866) | 54,333) | 54,921) | 54,748) | 54,012) | 53,959) | 53,516) | 51,952) | 51,765) | 52,233) | 52,598) | 52,932) | 53,904) | 53,977) | 54,573) | 55,363) | 37,734) | 37,166) | 24,121) | 24,318) | 25,586) | 26,016) | 26,236) | 26,046) | ||||||||
| Shareholders’ equity | 24,525) | 24,160) | 23,677) | 24,135) | 24,826) | 24,663) | 23,765) | 24,022) | 20,951) | 21,202) | 21,081) | 21,497) | 21,310) | 21,403) | 20,994) | 21,358) | 21,152) | 21,247) | 12,948) | 12,587) | 7,963) | 7,583) | 7,633) | 8,033) | 7,666) | 7,223) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Financial leverage1 | 2.23 | 2.21 | 2.28 | 2.25 | 2.21 | 2.22 | 2.27 | 2.25 | 2.55 | 2.45 | 2.46 | 2.43 | 2.47 | 2.47 | 2.57 | 2.53 | 2.58 | 2.61 | 2.91 | 2.95 | 3.03 | 3.21 | 3.35 | 3.24 | 3.42 | 3.61 | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 2.03 | 2.09 | 2.10 | 2.14 | 2.17 | 2.17 | 2.21 | 2.20 | 2.25 | 2.21 | 2.18 | 2.15 | 2.16 | 2.19 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 3.33 | 3.31 | 3.29 | 3.25 | 3.17 | 3.16 | 3.09 | 3.33 | 3.37 | 3.43 | 3.44 | 3.46 | 3.52 | 3.64 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 3.06 | 3.15 | 3.10 | 3.16 | 3.16 | 3.24 | 3.32 | 3.38 | 3.46 | 3.54 | 3.48 | 3.52 | 3.57 | 3.68 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 2.82 | 2.79 | 2.70 | 2.74 | 2.75 | 2.83 | 2.61 | 2.55 | 2.55 | 2.60 | 2.44 | 2.48 | 2.46 | 2.48 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 3.02 | 3.02 | 2.76 | 2.79 | 2.56 | 2.64 | 2.55 | 2.44 | 2.67 | 2.80 | 2.42 | 2.52 | 2.44 | 2.61 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 1.14 | 1.13 | 1.14 | 1.13 | 1.13 | 1.14 | 1.15 | 1.15 | 1.16 | 1.16 | 1.18 | 1.18 | 1.17 | 1.17 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 1.76 | 1.78 | 1.81 | 1.92 | 1.91 | 1.87 | 1.79 | 1.79 | 1.80 | 1.81 | 1.79 | 1.78 | 1.78 | 1.79 | 1.80 | 1.91 | 1.84 | 1.98 | — | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 1.37 | 1.39 | 1.43 | 1.36 | 1.33 | 1.32 | 1.21 | 1.18 | 1.17 | 1.24 | 1.20 | 1.27 | 1.23 | 1.22 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 3.16 | 3.04 | 2.96 | 3.03 | 3.05 | 3.09 | 3.01 | 2.93 | 3.03 | 3.32 | 3.02 | 3.16 | 3.15 | 3.12 | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).
1 Q2 2022 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 54,786 ÷ 24,525 = 2.23
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Becton, Dickinson & Co. financial leverage ratio decreased from Q4 2021 to Q1 2022 but then slightly increased from Q1 2022 to Q2 2022. |
Interest Coverage
Becton, Dickinson & Co., interest coverage calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||||||
| Net income (loss) | 454) | 677) | 265) | 525) | 299) | 1,003) | 127) | 286) | 183) | 278) | 163) | 451) | 20) | 599) | (135) | 594) | (12) | (136) | 326) | (132) | 344) | 562) | 19) | 390) | 338) | 229) | ||||||||
| Add: Income tax expense | 71) | 46) | 1) | (11) | 6) | 154) | 16) | (38) | 17) | 116) | (164) | 9) | (17) | 115) | 550) | 53) | 18) | 241) | —) | (272) | 18) | 130) | (9) | 32) | 38) | 37) | ||||||||
| Add: Interest expense | 101) | 98) | 112) | 115) | 124) | 118) | 123) | 135) | 134) | 136) | 141) | 156) | 171) | 171) | 181) | 182) | 185) | 158) | 156) | 184) | 86) | 95) | 95) | 97) | 99) | 97) | ||||||||
| Earnings before interest and tax (EBIT) | 626) | 821) | 378) | 629) | 429) | 1,275) | 266) | 383) | 334) | 530) | 140) | 616) | 174) | 885) | 596) | 829) | 191) | 263) | 482) | (220) | 448) | 787) | 105) | 519) | 475) | 363) | ||||||||
| Solvency Ratio | ||||||||||||||||||||||||||||||||||
| Interest coverage1 | 5.76 | 5.03 | 5.78 | 5.41 | 4.71 | 4.43 | 2.87 | 2.54 | 2.86 | 2.42 | 2.84 | 3.34 | 3.52 | 3.48 | 2.66 | 2.59 | 1.05 | 1.67 | 2.87 | 2.43 | 4.98 | 4.89 | 3.77 | — | — | — | ||||||||
| Benchmarks | ||||||||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 20.07 | 18.10 | 16.41 | 16.38 | 14.28 | 12.77 | 10.10 | 7.66 | 6.80 | 7.39 | 7.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 5.49 | 5.27 | 5.16 | 4.92 | 4.60 | 4.52 | 4.36 | 4.67 | 4.76 | 4.29 | 3.96 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 10.71 | 11.01 | 10.93 | 10.04 | 8.03 | 9.09 | 8.96 | 9.59 | 11.16 | 9.14 | 9.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 11.61 | 11.27 | 11.49 | 10.87 | 11.78 | 18.22 | 17.52 | 22.25 | 19.81 | 15.36 | 15.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 10.18 | 5.65 | 5.21 | 3.68 | 4.02 | 6.60 | 4.71 | 4.12 | 3.84 | 3.76 | 4.60 | 6.40 | 5.94 | 6.14 | 5.95 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Shockwave Medical Inc. | 53.60 | 28.23 | -7.06 | -33.01 | -40.84 | -55.47 | -53.14 | -57.89 | -61.51 | -57.41 | -53.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 14.45 | 14.26 | 14.44 | 13.46 | 13.03 | 14.88 | 13.47 | 14.12 | 13.89 | 11.40 | 11.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31), 10-K (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-Q (reporting date: 2015-12-31).
1 Q2 2022 Calculation
Interest coverage
= (EBITQ2 2022
+ EBITQ1 2022
+ EBITQ4 2021
+ EBITQ3 2021)
÷ (Interest expenseQ2 2022
+ Interest expenseQ1 2022
+ Interest expenseQ4 2021
+ Interest expenseQ3 2021)
= (626 + 821 + 378 + 629)
÷ (101 + 98 + 112 + 115)
= 5.76
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Becton, Dickinson & Co. interest coverage ratio deteriorated from Q4 2021 to Q1 2022 but then improved from Q1 2022 to Q2 2022 not reaching Q4 2021 level. |